Endocrine Abstracts

Objective: PWS is associated with hypogonadism and partial GH insufficiency. In addition partial insufficiency of the hypothalamic–pituitary–adrenal (HPA) axis recently was suggested (de Lind van Wijngaarden 2008) based upon an insufficient response to an overnight single-dose metyrapone in 15 out of 25 (60%) children. We aimed at further exploring this potentially dangerous condition.Methods: During a 1-year period genetically verified PWS pat...

Background: Prader-Willi syndrome (PWS) is a rare genetic, neurodevelopmental disorder. In adults the syndrome is characterized by muscular hypotonia, hyperphagia, increased risk of morbid obesity and behavioral problems. Endocrine insufficiencies are common, although insufficient function of the hypothalamus-pituitary-adrenal (HPA) axis seems to be rare. The effect of long term exposure to cortisol, which is associated with stress and obesity, is unknown in PWS. Measurement o...

Introduction: Omnitrope® (Sandoz) is a recombinant human growth hormone (rhGH) and was the first biosimilar medicine approved by the European Medicines Agency. PATRO Adults is an international, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope® in adults treated in routine clinical practice. The study provides data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here we pr...

Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35–<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...

Introduction: PATRO adults is an ongoing, international, open, longitudinal, non-interventional study of the long-term safety and efficacy of recombinant human GH (rhGH; Omnitrope, Sandoz). The study will provide further data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Adults who are receiving treatment with Omnitrope and who have provided informed conse...

Introduction: PATRO adults is an ongoing, international, open, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope (Sandoz), a recombinant human GH (rhGH). This study will provide additional data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Eligible patients are male or female adults who are receiving treatment with Om...

Background: Diabetes mellitus is prevalent in adults with Prader–Willi syndrome (PWS), and GH therapy may deteriorate glucose balance.Design: We prospectively investigated effects of 12 months of GH treatment on body composition and insulin resistance in relation to BMI in forty-two adults, mean(±S.D.) age 28.5±6.7 years with genetically verified PWS. Three patients with known diabetes were excluded. Data from baseline and 1...

Background: Serum IGFI measurements are used during GH replacement in GHDA for titration of the GH dose, to monitor compliance and to avoid overdosing, but it is uncertain if pretreatment IGFI is a determinant of the GH dose or the response to GH treatment.Methods: Data from the NordiNet IOS have been analyzed to determine pretreatment serum IGFI concentrations in GHDA and to analyze if they influence the GH starting dose and/or the therapeutic response ...

Introduction: Prader–Willi syndrome (PWS) presents clinically with a multitude of findings, including abnormal body composition and partial GH deficiency. Until now three studies have reported beneficial effects upon body composition of GH treatment in adults with PWS. However, only one of these studies had the optimal randomised controlled design.Aim: The aim of this study was to confirm and substantiate the results from previous studies.<p cla...

Background: The aim of the Swedish Pituitary Register – the Swedish Pituitary Study Group’s quality register – is to guarantee that all patients with pituitary tumours get equivalent diagnostic evaluation and treatment, as well as to evaluate given therapy. In this study, patients diagnosed with acromegaly from 1991 are described.Methods: Data from 557 patients (275 men/282 women), median age 51 years (range 4–87), with acromegaly wer...